Trial Profile
A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Feb 2019
Price :
$35
*
At a glance
- Drugs Dalteparin sodium (Primary)
- Indications Thromboembolism
- Focus Therapeutic Use
- Acronyms D-KAF
- 05 Feb 2019 New Source identified and Integrated (ISRCTN Current Controlled Trials: ISRCTN23254458 )
- 11 Dec 2005 New trial record.